Abstract:Abstract Background Urokinase (uPA) and its receptor (uPAR) play an important role in tumour growth and metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. Targeting the excessive activation of this system as well as the proliferation of the tumour vascular endothelial cell would be expected to prevent tumour neovasculature and halt tumour development. The amino terminal fragment (ATF) of urokinase has been confirmed effective to inhibit the proliferation, migration and invasiveness of cancer cells via interrupting the interaction of uPA and uPAR. Triptolide (TPL) is a purified diterpenoid isolated from the Chinese herb Tripterygium wilfordii Hook F that has shown antitumor activities in various cancer cell types. However, its therapeutic application is limited by its toxicity in normal tissues and complications caused in patients. In this study, we attempted to investigate the synergistic anticancer activity of TPL and ATF in various solid tumour cells. Methods Using in vitro and in vivo experiments, we investigated the combined effect of TPL and ATF at a low dosage on cell proliferation, cell apoptosis, cell cycle distribution, cell migration, signalling pathways, xenograft tumour growth and angiogenesis. Results Our data showed that the sensitivity of a combined therapy using TPL and ATF was higher than that of TPL or ATF alone. Suppression of NF-κB transcriptional activity, activation of caspase-9/caspase-3, cell cycle arrest, and inhibition of uPAR-mediated signalling pathway contributed to the synergistic effects of this combination therapy. Furthermore, using a mouse xenograft model, we demonstrated that the combined treatment completely suppressed tumour growth by inhibiting angiogenesis as compared with ATF or TPL treatment alone. Conclusions Our study suggests that lower concentration of ATF and TPL used in combination may produce a synergistic anticancer efficacy that warrants further investigation for its potential clinical applications.

In vitro synergistic cytotoxic effect of triptolide combined with hydroxycamptothecin on pancreatic cancer cells.

Targeting pancreatic cancer cells by a novel hydroxamate-based histone deacetylase (HDAC) inhibitor ST-3595

Triptolide sensitizes pancreatic cancer cells to TRAIL-induced activation of the death receptor pathway

Enhanced Proliferation Inhibition and Apoptosis in Glioma Cells Elicited by Combination of Irinotecan and Imatinib

Triptolide synergistically enhances antitumor activity of oxaliplatin in colon carcinoma in vitro and in vivo

Perspectives on the Combination of Radiotherapy and Targeted Therapy with DNA Repair Inhibitors in the Treatment of Pancreatic Cancer.

Herbal Compound Triptolide Synergistically Enhanced Antitumor Activity of Vasostatin120-180

Inhibition effects of TRAIL combined with small molecule drugs on pancreatic cancer cells

Combination of cycling hyperthermia and Echinacoside creates synergistic curing effect on pancreatic cancer PANC-1 cells

Combinatorial Treatment of Tinzaparin and Chemotherapy can Induce a Significant Antitumor Effectin Pancreatic Cancer

Synergistic co-induction of apoptosis of pancreatic cancer cell line by all-trans retinoic acid and arsenic trioxide

Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine

Herbal compound triptolide synergistically enhanced antitumor activity of amino-terminal fragment of urokinase

(3E,5E)-3,5-Bis(pyridin-3-methylene)-tetrahydrothiopyran-4-one enhances the inhibitory effect of gemcitabine on pancreatic cancer cells

Synergistic Efficacy of CDK4/6 Inhibitor Abemaciclib and HDAC Inhibitor Panobinostat in Pancreatic Cancer Cells

Single Dual-specific Anti-PD-L1/TGF-β Antibody Synergizes with Chemotherapy as Neoadjuvant Treatment for Pancreatic Ductal Adenocarcinoma: a Preclinical Experimental Study

Synergistic Anticancer Activity of Plumbagin and Xanthohumol Combination on Pancreatic Cancer Models

Combination therapy with interleukin-15 and metformin as a synergistic treatment for pancreatic cancer

Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer

Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures

Combination of baicalein and 10-hydroxy camptothecin exerts remarkable synergetic anti-cancer effects